Sarcopenia and Dynapenia Study in Multiple Sclerosis Patients
This study aims to assess the prevalence of sarcopenia and dynapenia in 150 patients with multiple sclerosis, categorized by their disability levels using EDSS scores. It is designed as a cross-sectional observational analysis with no sample randomization or results available yet.
- Tags
- #MSResearch
- Most relevant to
- —
- Source
- Read original source
Why it matters
Understanding the prevalence of sarcopenia and dynapenia in MS patients can inform about the impact of these conditions on disability and clinical outcomes, potentially guiding future research.
What this does not prove
Currently, no results are available, and the study has not been randomized, limiting insights into causation and broader applicability.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- 150 · basis not reported
- Randomised
- No
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- Not reported
- Evidence reviewed
- Trial registry record
- Regulatory approval
- No
- Research areas
- Not classified
Original sources
Supporting passages (6)
sample size150
randomizedNo
regulatory approvalNo
primary endpointThe prevalence of sarcopenia and dynapenia will be compared between disability groups, and associations with clinical and functional parameters will be examined."
findings"briefSummary": "This cross-sectional observational study aims to determine the prevalence of sarcopenia and dynapenia across disability stages in patients with multiple sclerosis (MS) and investigate their associations with clinical and functional parameters.
limitationsNo results are posted.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.